SCHEMBL3038784

SCHEMBL3038784

O=Cc1ccc(-c2ccccc2Oc2ccccc2)o1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 10/20 0.55
LMNA P02545 3/20 0.55
POLB P06746 3/20 0.55
SLC9A1 P19634 1/20 0.51
ALDH1A1 P00352 8/20 0.50
KMT2A Q03164 4/20 0.49
GAA P10253 2/20 0.49
HPGD P15428 3/20 0.47
L3MBTL1 Q9Y468 2/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
MAPT P10636 4/20 0.44
MEN1 O00255 3/20 0.42
RECQL P46063 2/20 0.42
TSHR P16473 1/20 0.41
PKM P14618 2/20 0.41
GLA P06280 1/20 0.41
TDP1 Q9NUW8 3/20 0.41
HSD17B10 Q99714 1/20 0.41
EIF4A1 P60842 1/20 0.40
PTGS2 P35354 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2551317 0.81 KDM4E (0.66) KDM4ELMNAPOLBSLC9A1ALDH1A1
SCHEMBL3039674 0.78 KDM4E (0.51) KDM4ELMNAPOLBALDH1A1HPGD
SCHEMBL3038241 0.78 KDM4E (0.57) KDM4ELMNAPOLBALDH1A1KMT2A
SCHEMBL3634969 0.77 ALDH1A1 (0.68) KDM4ELMNAPOLBALDH1A1KMT2A
SCHEMBL6009527 0.77 ALDH1A1 (0.59) KDM4ELMNAPOLBSLC9A1ALDH1A1
SCHEMBL6010447 0.77 ALDH1A1 (0.52) KDM4ELMNAPOLBSLC9A1ALDH1A1
SCHEMBL8412536 0.75 ALDH1A1 (0.59) KDM4ELMNAPOLBALDH1A1KMT2A
SCHEMBL6656195 0.73 ALDH1A1 (0.61) KDM4ELMNAPOLBALDH1A1KMT2A
SCHEMBL1680731 0.73 LMNA (0.48) KDM4ELMNAPOLBALDH1A1KMT2A
SCHEMBL30175832 0.73 SLC9A1 (0.66) KDM4ESLC9A1ALDH1A1KMT2AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8338465-B2 Cyclic carboxylic acid rhodanine derivatives for the treatment and prevention of tuberculosis CORNELL RESEARCH FOUNDATION, INC. (US) 2012-12-25 US disclosed
US-20100210577-A1 CYCLIC CARBOXYLIC ACID RHODANINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF TUBERCULOSIS CORNELL RESEARCH FOUNDATION, INC. 2010-08-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100210577-A1 CYCLIC CARBOXYLIC ACID RHODANINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF TUBERCULOSIS RARG, SDHA, RARS2 KDM4E 4138/4885LMNA 3523/4885POLB 1558/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.